S&P 500   3,961.34 (-0.41%)
DOW   32,358.83 (-0.23%)
QQQ   306.05 (-0.88%)
AAPL   156.70 (-1.00%)
MSFT   273.47 (-1.05%)
META   199.89 (-1.45%)
GOOGL   100.94 (-1.48%)
AMZN   96.91 (-1.15%)
TSLA   187.84 (-2.07%)
NVDA   262.60 (-1.02%)
NIO   9.19 (+2.91%)
BABA   98.59 (+14.48%)
AMD   94.08 (-2.62%)
T   18.81 (-0.32%)
F   11.60 (+0.69%)
MU   58.98 (-1.35%)
CGC   1.82 (-3.46%)
GE   92.92 (-0.42%)
DIS   95.02 (-0.63%)
AMC   5.44 (+19.56%)
PYPL   72.36 (-1.28%)
PFE   39.99 (-0.57%)
NFLX   323.98 (-1.12%)
S&P 500   3,961.34 (-0.41%)
DOW   32,358.83 (-0.23%)
QQQ   306.05 (-0.88%)
AAPL   156.70 (-1.00%)
MSFT   273.47 (-1.05%)
META   199.89 (-1.45%)
GOOGL   100.94 (-1.48%)
AMZN   96.91 (-1.15%)
TSLA   187.84 (-2.07%)
NVDA   262.60 (-1.02%)
NIO   9.19 (+2.91%)
BABA   98.59 (+14.48%)
AMD   94.08 (-2.62%)
T   18.81 (-0.32%)
F   11.60 (+0.69%)
MU   58.98 (-1.35%)
CGC   1.82 (-3.46%)
GE   92.92 (-0.42%)
DIS   95.02 (-0.63%)
AMC   5.44 (+19.56%)
PYPL   72.36 (-1.28%)
PFE   39.99 (-0.57%)
NFLX   323.98 (-1.12%)
S&P 500   3,961.34 (-0.41%)
DOW   32,358.83 (-0.23%)
QQQ   306.05 (-0.88%)
AAPL   156.70 (-1.00%)
MSFT   273.47 (-1.05%)
META   199.89 (-1.45%)
GOOGL   100.94 (-1.48%)
AMZN   96.91 (-1.15%)
TSLA   187.84 (-2.07%)
NVDA   262.60 (-1.02%)
NIO   9.19 (+2.91%)
BABA   98.59 (+14.48%)
AMD   94.08 (-2.62%)
T   18.81 (-0.32%)
F   11.60 (+0.69%)
MU   58.98 (-1.35%)
CGC   1.82 (-3.46%)
GE   92.92 (-0.42%)
DIS   95.02 (-0.63%)
AMC   5.44 (+19.56%)
PYPL   72.36 (-1.28%)
PFE   39.99 (-0.57%)
NFLX   323.98 (-1.12%)
S&P 500   3,961.34 (-0.41%)
DOW   32,358.83 (-0.23%)
QQQ   306.05 (-0.88%)
AAPL   156.70 (-1.00%)
MSFT   273.47 (-1.05%)
META   199.89 (-1.45%)
GOOGL   100.94 (-1.48%)
AMZN   96.91 (-1.15%)
TSLA   187.84 (-2.07%)
NVDA   262.60 (-1.02%)
NIO   9.19 (+2.91%)
BABA   98.59 (+14.48%)
AMD   94.08 (-2.62%)
T   18.81 (-0.32%)
F   11.60 (+0.69%)
MU   58.98 (-1.35%)
CGC   1.82 (-3.46%)
GE   92.92 (-0.42%)
DIS   95.02 (-0.63%)
AMC   5.44 (+19.56%)
PYPL   72.36 (-1.28%)
PFE   39.99 (-0.57%)
NFLX   323.98 (-1.12%)
NASDAQ:HCM

HUTCHMED - HCM Stock Forecast, Price & News

$13.70
-0.11 (-0.80%)
(As of 03/28/2023 02:43 PM ET)
Add
Compare
Today's Range
$13.34
▼
$13.70
50-Day Range
$13.43
▼
$19.87
52-Week Range
$7.39
▼
$21.28
Volume
38,356 shs
Average Volume
255,381 shs
Market Capitalization
$2.37 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.00

HUTCHMED MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
17.2% Upside
$16.00 Price Target
Short Interest
Healthy
0.35% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.59mentions of HUTCHMED in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.98) to ($0.59) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.64 out of 5 stars

Medical Sector

878th out of 1,002 stocks

Pharmaceutical Preparations Industry

425th out of 488 stocks

See Top Rated MarketRank™ Stocks Here

HCM stock logo

About HUTCHMED (NASDAQ:HCM) Stock

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.

Receive HCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for HUTCHMED and its competitors with MarketBeat's FREE daily newsletter.

HCM Stock News Headlines

March 25, 2023 | americanbankingnews.com
HUTCHMED (NASDAQ:HCM) Trading Down 3.7%
March 12, 2023 | finance.yahoo.com
HUTCHMED Confirms No Assets Held at Silicon Valley Bank
March 28, 2023 | Investor Place Media (Ad)
The "King Of Quants" sees 10X potential...
Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...
January 23, 2023 | finance.yahoo.com
HUTCHMED Out Licenses Fruquintinib To Takeda Outside China
January 23, 2023 | markets.businessinsider.com
Takeda To Pay Up To $1.13 Bln To HUTCHMED For Exclusive License Of Fruquintinib Outside China
January 1, 2023 | finance.yahoo.com
HUTCHMED (China) Limited (HCM)
November 14, 2022 | finance.yahoo.com
Hutchmed-Lilly Partnered Gastric Cancer Drug Shows Mixed Results In Phase 3 Study
November 13, 2022 | finance.yahoo.com
HUTCHMED Announces Positive Topline Result in Fruquintinib Phase III FRUTIGA Study in Second-Line Gastric Cancer in China
March 28, 2023 | Weiss Ratings (Ad)
Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
October 10, 2022 | finance.yahoo.com
HUTCHMED Initiates a Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China - Yahoo Finance
October 10, 2022 | globenewswire.com
HUTCHMED Initiates a Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China - GlobeNewswire
October 10, 2022 | finance.yahoo.com
HUTCHMED Initiates a Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
August 23, 2022 | finance.yahoo.com
HUTCHMED Highlights Fruquintinib MRCT FRESCO-2 Data to be Presented at the Upcoming ESMO Congress 2022 - Yahoo Finance
August 9, 2022 | streetinsider.com
HUTCHMED and AstraZeneca Announce that TAGRISSO® Plus Savolitinib Demonstrated 49% Objective Response Rate in Lung Cancer Patients with High Levels of MET Overexpression and/or Amplification in - StreetInsider.com
August 9, 2022 | streetinsider.com
Form 6-K HUTCHMED (China) Ltd For: Aug 09 - StreetInsider.com
August 9, 2022 | globenewswire.com
Inmagene and HUTCHMED Announce First Participant in Global Phase I Trial of IMG-004 - GlobeNewswire
August 8, 2022 | businesswire.com
TAGRISSO® plus savolitinib demonstrated 49% objective response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial - Business Wire
August 8, 2022 | benzinga.com
Recap of Monday’s Biotech Catalysts - End Of the Day Summary - Benzinga
August 8, 2022 | seekingalpha.com
AstraZeneca, Hutchmed savolitinib/ Tagrisso shows response in some lung cancer patients - Seeking Alpha
August 8, 2022 | streetinsider.com
Form 6-K HUTCHMED (China) Ltd For: Aug 08 - StreetInsider.com
August 7, 2022 | globenewswire.com
HUTCHMED Announces that Fruquintinib Global Phase III FRESCO-2 Study Has Met Its Primary Endpoint in Metastatic Colorectal Cancer - GlobeNewswire
August 7, 2022 | finance.yahoo.com
HUTCHMED Announces that Fruquintinib Global Phase III FRESCO-2 Study Has Met Its Primary Endpoint in Metastatic Colorectal Cancer
August 1, 2022 | benzinga.com
HUTCHMED (China) shares are trading lower after the company reported first half of 2022 financial results - Benzinga
August 1, 2022 | investing.com
HUTCHMED DRC Earnings Miss, Revenue Beats In Q2 By Investing.com - Investing.com
August 1, 2022 | morningstar.com
FTSE 100 Closed Down 0.14% Amid Asia Tensions - Morningstar
August 1, 2022 | seekingalpha.com
Hutchmed begins dosing in mid-stage study of tazemetostat in blood cancer subtype - Seeking Alpha
August 1, 2022 | marketwatch.com
Hutchmed (China) 1H Pretax Loss Widened After Costs Rise - MarketWatch
See More Headlines
Receive HCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for HUTCHMED and its competitors with MarketBeat's FREE daily newsletter.

HCM Company Calendar

Today
3/28/2023
Next Earnings (Estimated)
5/23/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HCM
CUSIP
N/A
CIK
1648257
Web
www.chi-med.com
Phone
852-2121-3888
Fax
852-2128-1778
Employees
2,025
Year Founded
2000

Price Target and Rating

Average Stock Price Forecast
$16.00
High Stock Price Forecast
$16.00
Low Stock Price Forecast
$16.00
Forecasted Upside/Downside
+15.9%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
0.03
Current Ratio
2.37
Quick Ratio
2.21

Sales & Book Value

Annual Sales
$426.41 million
Price / Sales
5.60
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.68 per share
Price / Book
3.75

Miscellaneous

Outstanding Shares
172,960,000
Free Float
166,729,000
Market Cap
$2.39 billion
Optionable
Not Optionable
Beta
1.04

Social Links


Key Executives

  • Mr. Chi Keung To ACGI (Age 71)
    B.Sc., BSc, M.B.A., MBA, Exec. Chairman
    Comp: $85k
  • Dr. Weiguo Su B.Sc. (Age 66)
    Ph.D., CEO, Chief Scientific Officer & Exec. Director
    Comp: $1.36M
  • Mr. Chig Fung Cheng BEc (Age 56)
    CA, CFO & Exec. Director
    Comp: $838.51k
  • Ms. Edith Shih C.S. (Age 71)
    CGP, FCS, M.A., P.E., BSE, EdM, Solicito, Company Sec. & Non-Exec. Director
    Comp: $74.3k
  • Dr. Karen Jane Atkin (Age 57)
    Exec. VP & COO
  • Mr. Kin Hung Lee M.B.A. (Age 46)
    Sr. VP of Corp. Fin. & Devel.
  • Mr. Charles George Rupert Nixon (Age 53)
    Group Gen. Counsel
  • Ms. Selina Zhang
    Sr. VP of Global HR
  • Dr. Qingmei Wang Ph.D. (Age 60)
    Sr. VP of Bus. Devel. & Strategic Alliances
  • Mr. Hong Chen (Age 53)
    Sr. VP & Chief Commercial Officer- China

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













HCM Stock - Frequently Asked Questions

Should I buy or sell HUTCHMED stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for HUTCHMED in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" HCM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HCM, but not buy additional shares or sell existing shares.
View HCM analyst ratings or view top-rated stocks.

What is HUTCHMED's stock price forecast for 2023?

3 Wall Street research analysts have issued twelve-month price targets for HUTCHMED's shares. Their HCM share price forecasts range from $16.00 to $16.00. On average, they anticipate the company's stock price to reach $16.00 in the next year. This suggests a possible upside of 15.9% from the stock's current price.
View analysts price targets for HCM or view top-rated stocks among Wall Street analysts.

How have HCM shares performed in 2023?

HUTCHMED's stock was trading at $14.78 on January 1st, 2023. Since then, HCM stock has decreased by 6.6% and is now trading at $13.81.
View the best growth stocks for 2023 here.

Are investors shorting HUTCHMED?

HUTCHMED saw a decrease in short interest in the month of March. As of March 15th, there was short interest totaling 610,900 shares, a decrease of 10.0% from the February 28th total of 679,000 shares. Based on an average daily volume of 262,700 shares, the days-to-cover ratio is currently 2.3 days.
View HUTCHMED's Short Interest.

When is HUTCHMED's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 23rd 2023.
View our HCM earnings forecast.

What ETFs hold HUTCHMED's stock?

ETFs with the largest weight of HUTCHMED (NASDAQ:HCM) stock in their portfolio include Loncar China BioPharma ETF (CHNA), Invesco Nasdaq Biotechnology ETF (IBBQ).ProShares Ultra Nasdaq Biotechnology (BIB) and

What other stocks do shareholders of HUTCHMED own?

Based on aggregate information from My MarketBeat watchlists, some companies that other HUTCHMED investors own include Telford Homes (TEF), AbbVie (ABBV), Exelixis (EXEL), GW Pharmaceuticals (GWPH), Premier Oil (PMO), CRISPR Therapeutics (CRSP), AT&T (T), Johnson & Johnson (JNJ), NVIDIA (NVDA) and Weyerhaeuser (WY).

When did HUTCHMED IPO?

(HCM) raised $100 million in an initial public offering (IPO) on Thursday, March 17th 2016. The company issued 6,100,000 shares at a price of $16.33 per share. BofA Merrill Lynch and Deutsche Bank Securities acted as the underwriters for the IPO and Stifel, Canaccord Genuity, Panmure Gordon and CITIC CLSA were co-managers.

What is HUTCHMED's stock symbol?

HUTCHMED trades on the NASDAQ under the ticker symbol "HCM."

Who are HUTCHMED's major shareholders?

HUTCHMED's stock is owned by a number of institutional and retail investors. Top institutional shareholders include M&G Investment Management Ltd. (4.34%), Schroder Investment Management Group (2.69%), Millennium Management LLC (0.50%), Cannon Global Investment Management LLC (0.38%), AIA Group Ltd (0.30%) and Jane Street Group LLC (0.23%).

How do I buy shares of HUTCHMED?

Shares of HCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is HUTCHMED's stock price today?

One share of HCM stock can currently be purchased for approximately $13.81.

How much money does HUTCHMED make?

HUTCHMED (NASDAQ:HCM) has a market capitalization of $2.39 billion and generates $426.41 million in revenue each year.

How many employees does HUTCHMED have?

The company employs 2,025 workers across the globe.

How can I contact HUTCHMED?

HUTCHMED's mailing address is 48TH FLOOR CHEUNG KONG CENTER 2 QUEEN`S ROAD CENTRAL, HONG KONG K3, . The official website for the company is www.chi-med.com. The company can be reached via phone at 852-2121-3888, via email at ir@chi-med.com, or via fax at 852-2128-1778.

This page (NASDAQ:HCM) was last updated on 3/28/2023 by MarketBeat.com Staff